Psychological Status of the Participants in Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia.

BACKGROUND: The SARS-CoV2 global pandemic impacted participants in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) clinical trial, who faced three stressors: 1) fear of developing dementia; 2) concerns about missing treatment; and 3) risk of SARS-CoV2 infection. OBJECTIVE: To describe the frequency of psychological disorders among the participants of the API ADAD Colombia clinical study, treated by a holistic mental health team during the COVID-19 pandemic. The extent of use of mental health team services was explored considering different risk factors, and users and non-users of these services were compared. METHODS: Participants had free and optional access to psychology and psychiatry services, outside of the study protocol. Descriptive statistics was used to analyze the frequency of the mental health difficulties. A multivariable logistic regression model has been used to assess associations with using this program. RESULTS: 66 participants were treated by the Mental Health Team from March 1, 2020, to December 31, 2020. Before and after the start of the pandemic, the most common psychological problems were anxiety (36.4% before, 63.6% after) and depression (34.8% before, 37.9% after). 70% of users assisted by psychology and 81.6% of those assisted by psychiatry felt that the services were useful for them. Female sex, depression, and anxiety before the pandemic were positively associated with being assisted by either psychology or psychiatry, while the association with hyperlipidemia was negative. CONCLUSIONS: A holistic mental health program, carried out in the context of a study, could mitigate psychopathology during pandemics such as COVID-19.

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.

INTRODUCTION: The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo-controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60-year-old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized to active treatment or placebo and non-carriers who receive placebo. METHODS: Of the 252 enrolled, we present data on a total of 242 mutation carriers and non-carriers matched by age range, excluding data on 10 participants to protect participant confidentiality, genetic status, and trial integrity. RESULTS: We summarize demographic, clinical, cognitive, and behavioral data from 167 mutation carriers and 75 non-carriers, 30 to 53 years of age. Carriers were significantly younger than non-carriers ((mean age ± SD) 37 ± 5 vs 42 ± 6), had significantly lower Mini Mental Status Exam (MMSE) scores (28.8 ± 1.4 vs 29.2 ± 1.0), and had consistently lower memory scores. DISCUSSION: Although PSEN1 E280A mutation carriers in the Trial are cognitively unimpaired, they have slightly lower MMSE and memory scores than non-carriers. Their demographic characteristics are representative of the local population.

CAP--advancing the evaluation of preclinical Alzheimer disease treatments.

If we are to find treatments to postpone, reduce the risk of, or completely prevent the clinical onset of Alzheimer disease (AD), we need faster methods to evaluate promising preclinical AD treatments, new ways to work together in support of common goals, and a determination to expedite the initiation and performance of preclinical AD trials. In this article, we note some of the current challenges, opportunities and emerging strategies in preclinical AD treatment. We describe the Collaboration for Alzheimer's Prevention (CAP)-a convening, harmonizing and consensus-building initiative to help stakeholders advance AD prevention research with rigour, care and maximal impact-and we demonstrate the impact of CAP on the goals and design of new preclinical AD trials.

Diagnóstico del estado nutricional de los pacientes con demencia tipo Alzheimer registrados en el Grupo de Neurociencias, Medellín, 2004 / Nutritional condition in patients with Alzheimer type dementia from the neurosciences group, Medellín 2004

Introducción. Los pacientes con demencia tipo Alzheimer presentan riesgo de deterioro del estado nutricional por cambios fisiológicos, socioeconómicos y psicológicos relacionados con la enfermedad, lo que se suma al proceso de envejecimiento. Objetivo. Describir el estado nutricional de los pacientes con demencia tipo Alzheimer del Grupo de Neurociencias de la Universidad de Antioquia según el estadio de evolución. Materiales y métodos. Estudio descriptivo transversal. Cada paciente fue evaluado para obtener información general, de salud, composición corporal, alimentaria, signos clínicos y aspectos psicosociales. Resultados. Se evaluaron 77 pacientes con edad promedio de 65,5±12,8 años, 48 de ellos con antecedentes familiares de la enfermedad y 39 con más de 60 meses de diagnóstico; el estadio más frecuente fue el moderado y el tipo de demencia más común, la familiar precoz; la enfermedad se diagnosticó antes de los 50 años en 26 pacientes. Hubo diferencias estadísticamente significativas en el índice de masa corporal, el área grasa braquial y el área magra braquial por estadio, y mayor compromiso en el estadio grave ( p=0,001, p=0,000 y p=0,000); en todos los estadios se presentó compromiso de la reserva energética y muscular. El calcio y los folatos fueron los nutrientes más comprometidos en el consumo. Conclusión. Aun en el estadio inicial, los pacientes presentaron compromiso del estado nutricional, evidenciado por déficit en la reserva energética y muscular, signos clínicos y consumo inadecuado de calcio y folatos. A medida que avanza la enfermedad, el compromiso de los indicadores nutricionales es mayor. Lo anterior evidencia la necesidad del cuidado nutricional individual de acuerdo con el estadio de la enfermedad.